Moreover, attenuating KAT5 expression followed by standard of care (temozolomide + fractionated radiation) significantly reduced tumor growth post-SOC and provided a significant survival benefit (Fig. 6g, h; Supplementary Fig. 13a). This evidence concerns the gene KAT5 and neoplasm.